General Information of Drug (ID: DM4E9PK)

Drug Name
AM-111 Drug Info
Synonyms
UNII-FU288768DP; FU288768DP; XG102 peptide; AM111 peptide; D-JNKI-1; D-JNKI 1 peptide; XG 102; AM 111; D-JNKI 1; TAT-IB1 fusion peptide XG-102 (synthetic); HIV TAT-JIP-1 fusion peptide XG-102 (synthetic); 1198367-70-2; 1148126-36-6; Glycine, D-alpha-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-
Indication
Disease Entry ICD 11 Status REF
Neurological disorder 6B60 Phase 3 [1]
Cross-matching ID
PubChem CID
72941992
CAS Number
CAS 1198367-70-2
TTD Drug ID
DM4E9PK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug(s) Targeting Jun N terminal kinase (JNK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BGP-15 DMYDM68 Type-2 diabetes 5A11 Phase 2 [3]
CC-401 DMPMO6G Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
CC-930 DMHVEGJ Discoid lupus erythematosus EB51.0 Phase 2 [5]
PMID25991433-Compound-Q1 DMEMSB2 N. A. N. A. Patented [6]
PMID25991433-Compound-O1 DMH073T N. A. N. A. Patented [6]
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Jun N terminal kinase (JNK) TTR2TXZ MK08_HUMAN; MK09_HUMAN; MK10_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02235272) Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation. U.S. National Institutes of Health.
2 The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
5 In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
6 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
7 c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.